88 related articles for article (PubMed ID: 8996987)
1. Pharmacokinetics of samarium-153-EDTMP in disseminated skeletal metastases.
Pusuwan P; Chaiwatanarat T; Chaudakshetrin P; Virawat N; Pattaranutaporn P; Chansilpa Y; Suntornpong N; Tocharoenchai C; Buranapong P; Chanachai R; Suputtamongkol Y; Pleehachinda R
J Med Assoc Thai; 1996 Sep; 79(9):579-84. PubMed ID: 8996987
[No Abstract] [Full Text] [Related]
2. Samarium 153Sm lexidronam.
Lamb HM; Faulds D
Drugs Aging; 1997 Nov; 11(5):413-8; discussion 419. PubMed ID: 9359026
[TBL] [Abstract][Full Text] [Related]
3. [Cost-effectiveness of samarium-153-EDTMP for the treatment of pain due to multiple bone metastases in hormone-refractory prostate cancer versus conventional pain therapy, in Portugal].
Macedo A; Araújo A; Melo FC; Nunes G; Cantinho G; Amorin I
Acta Med Port; 2006; 19(5):421-6. PubMed ID: 17376329
[TBL] [Abstract][Full Text] [Related]
4. Samarium-153 lexidronam for painful bone metastases.
Med Lett Drugs Ther; 1997 Aug; 39(1008):83-4. PubMed ID: 9286284
[No Abstract] [Full Text] [Related]
5. (153)Sm-EDTMP for pain relief of bone metastases from prostate and breast cancer and other malignancies.
Correa-González L; Arteaga de Murphy C; Pichardo-Romero P; Pedraza-López M; Moreno-García C; Correa-Hernández L
Arch Med Res; 2014 May; 45(4):301-8. PubMed ID: 24681187
[TBL] [Abstract][Full Text] [Related]
6. [153Sm-EDTMP for moderate and severe bone cancer pain].
Deng H; Luo S; Tan T; Mo T; Liang Z; Pu M; Jiao J; Zhong S; Wang Q; Hu Y
Hua Xi Yi Ke Da Xue Xue Bao; 1995 Dec; 26(4):391-4. PubMed ID: 8732058
[TBL] [Abstract][Full Text] [Related]
7. Biodistribution of samarium-153-EDTMP in rats treated with docetaxel.
Villarim Neto A; Açucena MK; Pereira KR; Rêgo AC; Azevedo IM; Bernardo-Filho M; Medeiros AC
Acta Cir Bras; 2009; 24(1):62-6. PubMed ID: 19169545
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases.
Turner JH; Claringbold PG; Hetherington EL; Sorby P; Martindale AA
J Clin Oncol; 1989 Dec; 7(12):1926-31. PubMed ID: 2585026
[TBL] [Abstract][Full Text] [Related]
9. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer.
Farhanghi M; Holmes RA; Volkert WA; Logan KW; Singh A
J Nucl Med; 1992 Aug; 33(8):1451-8. PubMed ID: 1378887
[TBL] [Abstract][Full Text] [Related]
10. Is ¹⁵³Samarium-ethylene-diamine-tetramethyl-phosphonate (EDTMP) bone uptake influenced by bisphosphonates in patients with castration-resistant prostate cancer?
Waldert M; Klatte T; Remzi M; Sinzinger H; Kratzik C
World J Urol; 2012 Apr; 30(2):233-7. PubMed ID: 21559805
[TBL] [Abstract][Full Text] [Related]
11. Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer.
Singh A; Holmes RA; Farhangi M; Volkert WA; Williams A; Stringham LM; Ketring AR
J Nucl Med; 1989 Nov; 30(11):1814-8. PubMed ID: 2478681
[TBL] [Abstract][Full Text] [Related]
12. Background, reasons and benefits using the vienna protocol for the treatment of painful bone recurrences with 153Samarium-EDTMP.
Sinzinger H; Weiss K; Hiltunen J
Anticancer Res; 2009 Aug; 29(8):3393-5. PubMed ID: 19661362
[TBL] [Abstract][Full Text] [Related]
13. Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis.
Serafini AN
Q J Nucl Med; 2001 Mar; 45(1):91-9. PubMed ID: 11456381
[TBL] [Abstract][Full Text] [Related]
14. Radionuclides for metastatic bone pain palliation: a need for rational re-evaluation in the new millennium.
Krishnamurthy GT; Krishnamurthy S
J Nucl Med; 2000 Apr; 41(4):688-91. PubMed ID: 10768570
[No Abstract] [Full Text] [Related]
15. Biospeciation, by potentiometry and computer simulation, of Sm-EDTMP, a bone tumor palliative agent.
Charmaine de Witt G; May PM; Webb J; Hefter G
Biometals; 1996 Oct; 9(4):351-61. PubMed ID: 8837456
[TBL] [Abstract][Full Text] [Related]
16. [Analgesic response and secondary effects in patients with osteoblastic metastasis, treated with Samarium 153 ethylenediaminotetramethylenephosphate].
Lovera C; Massardo T; Galleguillos MC; González P; Comparini B; Yáñez M; Fodor M; Gil MC; Araya G; Tomicic M
Rev Med Chil; 1998 Aug; 126(8):963-71. PubMed ID: 9830748
[TBL] [Abstract][Full Text] [Related]
17. A comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer.
Wang RF; Zhang CL; Zhu SL; Zhu M
Med Princ Pract; 2003; 12(2):97-101. PubMed ID: 12634464
[TBL] [Abstract][Full Text] [Related]
18. Optimal treatment of painful bone metastases with Samarium EDTMP in a haemodialysis patient: effectiveness and safety of internal radiotherapy.
Skalli S; Desruet MD; Bourre JC; Caravel JP; Vuillez JP
Nephrol Dial Transplant; 2009 Aug; 24(8):2598-600. PubMed ID: 19369693
[TBL] [Abstract][Full Text] [Related]
19. 177Lu-EDTMP: a potential therapeutic bone agent.
Ando A; Ando I; Tonami N; Kinuya S; Kazuma K; Kataiwa A; Nakagawa M; Fujita N
Nucl Med Commun; 1998 Jun; 19(6):587-91. PubMed ID: 10234664
[TBL] [Abstract][Full Text] [Related]
20. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases.
Bayouth JE; Macey DJ; Kasi LP; Fossella FV
J Nucl Med; 1994 Jan; 35(1):63-9. PubMed ID: 7505819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]